Terutroban sodium

Drug Profile

Terutroban sodium

Alternative Names: S-18886

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boston University Medical Campus; Servier
  • Developer Servier
  • Class Anti-ischaemics; Antiplatelets; Antithrombotics; Naphthalenes; Propionic acids; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Cerebral ischaemia; Coronary disorders; Peripheral vascular disorders; Thromboembolism

Most Recent Events

  • 03 Aug 2010 Servier terminates the phase III PERFORM trial in prevention of Thromboembolism (secondary prevention of ischaemic stroke)
  • 27 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the Thromboses pharmacodynamics section
  • 12 Jul 2007 Preclinical trials in Arterial thrombosis in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top